Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$146.50 USD
-0.62 (-0.42%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $146.42 -0.08 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NBIX 146.50 -0.62(-0.42%)
Will NBIX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Top Medical Stocks to Buy for Growth & Performance
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
Other News for NBIX
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Neurocrine (NBIX) Receives a Hold from Mizuho Securities
Wall Street Analysts Are Neutral on Top Healthcare Picks
Analysts’ Top Healthcare Picks: Editas Medicine (EDIT), Neurocrine (NBIX)
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Patterson Companies (PDCO) and Neurocrine (NBIX)